Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Mesoblast Limited American Depositary Shares (MESO)

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/20/2010

Market Cap

759,493,283

Shares Outstanding

1,015,340,000

Weighted SO

85,815,906

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

VIRI --.--%

ADTX --.--%

LPCN --.--%

APGN --.--%

CNTB --.--%

ABOS --.--%

ETON --.--%

NUVB --.--%

ELDN --.--%

Beta

2.4400

Last Div

0.0000

Range

1.61-8.66

Chg

0.2550

Avg Vol

182050

Mkt Cap

759493283

Exch

NASDAQ

Country

AU

Phone

61 3 9639 6036

DCF Diff

8.0673

DCF

-1.5173

Div Yield

0.0000

P/S

101.7269

EV Multiple

-14.1878

P/FV

11.1389

Div Yield %

0.0000

P/E

-77.5643

PEG

-11.9815

Payout

0.0000

Current Ratio

2.7148

Quick Ratio

2.7148

Cash Ratio

2.4594

DSO

195.4554

DIO

0.0000

Op Cycle

195.4554

DPO

114.2816

CCC

81.1739

Gross Margin

-3.6030

Op Margin

-7.9873

Pretax Margin

-9.8106

Net Margin

-9.7854

Eff Tax Rate

-0.0002

ROA

-0.1090

ROE

-0.1460

ROCE

-0.0933

NI/EBT

0.9974

EBT/EBIT

1.2283

EBIT/Rev

-7.9873

Debt Ratio

0.1820

D/E

0.2398

LT Debt/Cap

0.1786

Total Debt/Cap

0.1934

Int Coverage

-6.8090

CF/Debt

-0.3591

Equity Multi

1.3176

Rec Turnover

1.8674

Pay Turnover

3.1939

Inv Turnover

999999.9999

FA Turnover

1.3575

Asset Turnover

0.0111

OCF/Share

-0.0514

FCF/Share

-0.0518

Cash/Share

0.0906

OCF/Sales

-5.8677

FCF/OCF

1.0064

CF Coverage

-0.3591

ST Coverage

-3.8479

CapEx Coverage

-155.3475

Div&CapEx Cov

-155.3475

P/BV

11.1389

P/B

11.1389

P/S

101.7269

P/E

-77.5643

P/FCF

-17.2260

P/OCF

-129.3529

P/CF

-129.3529

PEG

-11.9815

P/S

101.7269

EV Multiple

-14.1878

P/FV

11.1389

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 18, 00:38 Successful Commercial Launch of Ryoncil® GlobeNewswire Inc. Jun 12, 01:24 Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD GlobeNewswire Inc. May 15, 02:57 FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® GlobeNewswire Inc. Apr 28, 23:44 Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board GlobeNewswire Inc. Apr 17, 01:20 Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives GlobeNewswire Inc. Apr 03, 22:58 Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs GlobeNewswire Inc. Apr 02, 23:15 Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure GlobeNewswire Inc. Mar 30, 23:39 First Three Children to Commence Treatment With Ryoncil® GlobeNewswire Inc. Mar 27, 00:19 Ryoncil® is Now Available for Purchase in the United States GlobeNewswire Inc. Mar 13, 23:42 Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States GlobeNewswire Inc. Feb 25, 23:13 Mesoblast Financial Results and Corporate Update Webcast GlobeNewswire Inc. Feb 23, 23:33 Dr. Gregory George MD PhD Joins Mesoblast Board GlobeNewswire Inc. Jan 31, 00:11 Ryoncil® Commercial Launch Update and Product Pipeline Benzinga Dec 16, 00:30 Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology GlobeNewswire Inc. Dec 16, 00:30 Stem Cell Banking Market to Surpass Value of USD 18.65 Billion By 2031 | SkyQuest Technology GlobeNewswire Inc. Sep 30, 00:55 Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch GlobeNewswire Inc. Sep 22, 04:30 Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight GlobeNewswire Inc. Aug 28, 23:27 Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 GlobeNewswire Inc. Aug 27, 23:25 Mesoblast Financial Results and Corporate Update Webcast The Motley Fool Jul 22, 01:23 Up 308% in 6 months, why is the Mesoblast share price tumbling today? - The Motley Fool Australia

Revenue Product Segmentation